Centrus Energy CorpLEU

Centrus Energy (LEU) announced a landmark $900 million contract with the U.S. Department of Energy to finalize its HALEU (High-Assay Low-Enriched Uranium) production cascade transition to commercial operation, building on a 2019 demonstration contract extended through June 2026. The deal underscores Centrus’s critical role in advancing domestic nuclear fuel capabilities, though the company’s latest financials reveal a mixed picture: Q1 2026 revenue of $76.7 million and net income of $10 million sit alongside a stark $35.1 million operating cash outflow and a ballooning inventory of $336 million.

As the self-proclaimed ‘world’s most diversified supplier of enriched uranium,’ Centrus serves civilian nuclear reactors and national security programs through advanced centrifuge technology and engineering services. Its Piketon, Ohio facility remains central to HALEU production ambitions, yet the balance sheet shows liabilities of $1.66 billion against $775.2 million in shareholder equity-a leverage ratio that would make even a centrifuge spin. The company’s $1.87 billion cash reserves offer comfort, but with R&D expenses of $18.9 million and capital expenditures of $23.2 million, the cash burn in core operations raises eyebrows.

Market participants will watch whether Centrus can convert the DOE’s largesse into sustainable earnings. The stock’s recent insider selling activity, including multiple June 2026 filings showing executives unloading shares, contrasts with the lack of buyback programs. The source directs readers to also monitor inventory levels, which grew 14% sequentially, and the dilution impact of 22.4 million diluted shares outstanding. Technical indicators, while absent from the evidence pack, will hinge on execution risks tied to the HALEU transition and customer diversification beyond government contracts.